Industry Briefs: December 3, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: December 3, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

AMRI will close its Bothell, Washington, site, and transition the site’s drug-discovery capabilities to Singapore while certain analytical capabilities will consolidate into the company’s analytical quality group in Albany, New York. Read More

Aptiv Solutions has opened a new laboratory and office in Durham, North Carolina. Read More

Bend Research, PATH, and Fraunhofer USA Center for Molecular Biotechnology (FhCMB) have developed a new technology for the production of thermostable vaccines. Read More

biOasis Technologies has entered into a research collaboration agreement with UCB to evaluate biOasis’s Transcend technology in the area of the delivery of therapeutic compounds to the brain. Read More

Capsugel has doubled its laboratory capacity with the opening of its new quality-control laboratory in Greenwood, South Carolina. Read More

Covance’s early-development facility in Shanghai, China, has received a Good Laboratory Practice Certificate from China’s State Food and Drug Administration. Read More

Dalton Pharma Services has added size-exclusion chromatography (SEC) - multi angle (laser) light-scattering (MALS) large-molecule testing services. Read More

Galena Biopharma has signed an agreement with a subsidiary of Teva Pharmaceutical Industries for the commercialization of NeuVax (nelipepimut-S or E75) in Israel. Read More

Hovione and Solvias have announced a collaboration focused on the development and GMP supply of pharmaceutical cocrystals. Read More

NextPharma has completed the sale of its Bioserv, its US affiliate, to KESA Partners. Read More

Noven Pharmaceuticals has acquired commercial rights to Minivelle (estradiol transdermal system) in the US and Canada. Read More

Recipharm has invested to expand its capacity in analytical services and stability studies at its facility in Solna, Sweden. Read More

Single Cell Technology and Open Monoclonal Technology have announced a human antibody discovery and development collaboration. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here